Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7999040 | 0.98 | TSHR (0.42) | TSHRPDE3BPDE3AP2RY12HPGD | |
| SCHEMBL18920642 | 0.95 | TSHR (0.45) | TSHRPDE3BPDE3AP2RY12HPGD | |
| SCHEMBL4811573 | 0.88 | TSHR (0.41) | TSHRPDE3BPDE3AHPGDLMNA | |
| SCHEMBL17242958 | 0.84 | CYP4F2 (0.44) | TSHRALDH1A1CA12CA1CA2 | |
| SCHEMBL1639509 | 0.84 | CA12 (0.38) | TSHRPDE3BPDE3AP2RY12HPGD | |
| SCHEMBL1639937 | 0.81 | PAOX (0.35) | ALDH1A1TBXAS1 | |
| SCHEMBL12118230 | 0.80 | PAOX (0.38) | ALDH1A1TBXAS1 | |
| SCHEMBL12287701 | 0.80 | PAOX (0.38) | ALDH1A1TBXAS1 | |
| SCHEMBL10435516 | 0.80 | TBXAS1 (0.47) | TSHRLMNAALDH1A1TBXAS1 | |
| SCHEMBL10678782 | 0.80 | TBXAS1 (0.33) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1320540-B9 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMA (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1876173-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1849797-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| EP-1320540-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| US-4766120-A | ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1988-08-23 | — | — | US | disclosed |
| US-4663323-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0035046-B1 | NOVEL TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4540703-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | disclosed |
| EP-0035046-A1 | Novel tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | CTRC, PEPD, CTSC | TSHR 1822/4885PDE3B 1087/4885PDE3A 779/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | TSHR 4389/4885PDE3B 386/4885PDE3A 444/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | TSHR 4389/4885PDE3B 386/4885PDE3A 444/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | TSHR 4606/4885PDE3B 341/4885PDE3A 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.